5-Hydroxytryptamine-3 receptor antagonist and dexamethasone as prophylaxis for chemotherapy-induced nausea and vomiting during moderately emetic chemotherapy for solid tumors: a multicenter, prospective, observational study
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
2050-6511
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
5-Hydroxytryptamine-3 receptor antagonist and dexamethasone as prophylaxis for chemotherapy-induced nausea and vomiting during moderately emetic chemotherapy for solid tumors: a multicenter, prospective, observational study ; volume:21 ; number:1 ; day:6 ; month:10 ; year:2020 ; pages:1-10 ; date:12.2020
BMC pharmacology & toxicology ; 21, Heft 1 (6.10.2020), 1-10, 12.2020
- Urheber
-
Matsui, Reiko
Suzuki, Kenichi
Takiguchi, Tomomi
Nishio, Makoto
Koike, Takeshi
Hayashi, Toshinobu
Seto, Takashi
Kogure, Yuki
Nogami, Naoyuki
Fujiwara, Kimiko
Kaneda, Hiroyasu
Harada, Tomohiko
Shimizu, Satoru
Kimura, Masashi
Kenmotsu, Hirotsugu
Shimokawa, Mototsugu
Goto, Koichi
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1186/s40360-020-00445-y
- URN
-
urn:nbn:de:101:1-2020112215402686638145
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:26 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Matsui, Reiko
- Suzuki, Kenichi
- Takiguchi, Tomomi
- Nishio, Makoto
- Koike, Takeshi
- Hayashi, Toshinobu
- Seto, Takashi
- Kogure, Yuki
- Nogami, Naoyuki
- Fujiwara, Kimiko
- Kaneda, Hiroyasu
- Harada, Tomohiko
- Shimizu, Satoru
- Kimura, Masashi
- Kenmotsu, Hirotsugu
- Shimokawa, Mototsugu
- Goto, Koichi
- SpringerLink (Online service)
Ähnliche Objekte (12)
Incidence of chemotherapy-induced nausea and vomiting with moderately emetogenic chemotherapy: ADVICE (Actual Data of Vomiting Incidence by Chemotherapy Evaluation) study
Netupitant/Palonosetron: A Review in Chemotherapy-Induced Nausea and Vomiting
Serum iron levels increased by cancer chemotherapy correlate the chemotherapy-induced nausea and vomiting
Efficacy of triple antiemetic therapy (palonosetron, dexamethasone, aprepitant) for chemotherapy-induced nausea and vomiting in patients receiving carboplatin-based, moderately emetogenic chemotherapy
Clinical research of Olanzapine for prevention of chemotherapy-induced nausea and vomiting
Correction to: Netupitant/Palonosetron: A Review in Chemotherapy-Induced Nausea and Vomiting
SEOM Clinical Guideline update for the prevention of chemotherapy-induced nausea and vomiting (2016)
A Study on Utilization and Evaluation of Antiemetics in Chemotherapy‑induced Nausea and Vomiting
Chemotherapy-induced nausea and vomiting in patients with breast cancer: a prospective cohort study
Olanzapine treatment effectively relieves breakthrough chemotherapy-induced nausea and vomiting: a real-world experience
Searching for perfection: further progress in management of chemotherapy-induced nausea and vomiting—introduction
Acupuncture Point Selection Patterns for Chemotherapy-Induced Nausea and Vomiting: A Data Mining Analysis
Incidence of chemotherapy-induced nausea and vomiting with moderately emetogenic chemotherapy: ADVICE (Actual Data of Vomiting Incidence by Chemotherapy Evaluation) study
Netupitant/Palonosetron: A Review in Chemotherapy-Induced Nausea and Vomiting
Serum iron levels increased by cancer chemotherapy correlate the chemotherapy-induced nausea and vomiting
Efficacy of triple antiemetic therapy (palonosetron, dexamethasone, aprepitant) for chemotherapy-induced nausea and vomiting in patients receiving carboplatin-based, moderately emetogenic chemotherapy
Clinical research of Olanzapine for prevention of chemotherapy-induced nausea and vomiting
Correction to: Netupitant/Palonosetron: A Review in Chemotherapy-Induced Nausea and Vomiting
SEOM Clinical Guideline update for the prevention of chemotherapy-induced nausea and vomiting (2016)
A Study on Utilization and Evaluation of Antiemetics in Chemotherapy‑induced Nausea and Vomiting
Chemotherapy-induced nausea and vomiting in patients with breast cancer: a prospective cohort study
Olanzapine treatment effectively relieves breakthrough chemotherapy-induced nausea and vomiting: a real-world experience
Searching for perfection: further progress in management of chemotherapy-induced nausea and vomiting—introduction
Acupuncture Point Selection Patterns for Chemotherapy-Induced Nausea and Vomiting: A Data Mining Analysis
Incidence of chemotherapy-induced nausea and vomiting with moderately emetogenic chemotherapy: ADVICE (Actual Data of Vomiting Incidence by Chemotherapy Evaluation) study
Netupitant/Palonosetron: A Review in Chemotherapy-Induced Nausea and Vomiting
Serum iron levels increased by cancer chemotherapy correlate the chemotherapy-induced nausea and vomiting
Efficacy of triple antiemetic therapy (palonosetron, dexamethasone, aprepitant) for chemotherapy-induced nausea and vomiting in patients receiving carboplatin-based, moderately emetogenic chemotherapy
Clinical research of Olanzapine for prevention of chemotherapy-induced nausea and vomiting
Correction to: Netupitant/Palonosetron: A Review in Chemotherapy-Induced Nausea and Vomiting
SEOM Clinical Guideline update for the prevention of chemotherapy-induced nausea and vomiting (2016)
A Study on Utilization and Evaluation of Antiemetics in Chemotherapy‑induced Nausea and Vomiting
Chemotherapy-induced nausea and vomiting in patients with breast cancer: a prospective cohort study
Olanzapine treatment effectively relieves breakthrough chemotherapy-induced nausea and vomiting: a real-world experience
Searching for perfection: further progress in management of chemotherapy-induced nausea and vomiting—introduction